270,000 Shares in Repligen Corporation $RGEN Acquired by Iron Triangle Partners LP

Iron Triangle Partners LP purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 270,000 shares of the biotechnology company’s stock, valued at approximately $36,091,000. Repligen makes up 5.1% of Iron Triangle Partners LP’s investment portfolio, making the stock its 8th biggest holding. Iron Triangle Partners LP owned about 0.48% of Repligen at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Balyasny Asset Management L.P. increased its holdings in shares of Repligen by 390.6% in the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock valued at $102,557,000 after purchasing an additional 610,837 shares during the period. Holocene Advisors LP raised its position in Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after buying an additional 440,290 shares during the last quarter. Blue Whale Capital LLP acquired a new stake in Repligen during the 2nd quarter valued at approximately $35,782,000. Schroder Investment Management Group boosted its holdings in shares of Repligen by 123.2% in the 3rd quarter. Schroder Investment Management Group now owns 460,609 shares of the biotechnology company’s stock valued at $61,570,000 after acquiring an additional 254,212 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Repligen in the second quarter worth $30,991,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Barclays dropped their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Wells Fargo & Company reduced their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, UBS Group dropped their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $174.58.

Insiders Place Their Bets

In related news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Repligen Stock Up 0.4%

Shares of RGEN opened at $114.20 on Monday. The firm has a market cap of $6.43 billion, a P/E ratio of 134.35, a PEG ratio of 2.23 and a beta of 1.15. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $175.77. The stock’s 50 day moving average is $145.43 and its two-hundred day moving average is $147.05. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business’s revenue was up 18.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.